
Jasper Therapeutics, Inc., (NASDAQ:JSPR) announced updated efficacy, safety and pharmacokinetic data from its Phase 1 clinical trial of JSP191, in older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic (blood) cell transplantation.
The data readout revealed, in Phase 1b dose expansion study, with 24 patients suffering from myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), JSP191 is well tolerated with no treatment-related severe adverse events.